Teva recalls cancer drug Adrucil after rubber particles discovered in vials

Teva Pharmaceutical Industries ($TEVA) is voluntarily recalling 8 lots of Adrucil, its version of the generic cancer treatment fluorouracil. The drugmaker said the recall was initiated after particulate was found in some vials that it identified as an aggregate of silicone rubber pieces from a filler diaphragm and fluorouracil crystals. Recall

Suggested Articles

Gilead expects to sell 1 million to 1.5 million treatment courses of remdesivir in 2020. That means about $3.5 billion in sales, one analsyt figures.

Pfizer and BioNTech followed supply pacts in the U.S. and U.K. with a new deal to deliver 120 million vaccines to Japan in the first half of 2021.

Warp Speed's largest outlay to date, the funding will cover development and manufacturing scale-up of a vaccine that uses proven Sanofi technology.